Home > Health & Medicine > 26th Annual Roth Conference

26th Annual Roth Conference

Date post: 05-Dec-2014
Category:
Author: cytori-therapeutics-inc
View: 326 times
Download: 2 times
Share this document with a friend
Description:
CFO Mark Saad presents at the 26th Annual Roth Conference on March 12, 2014
Embed Size (px)
of 27 /27
Cytori Corporate Overview NASDAQ: CYTX 26 th Annual Roth Conference March 12, 2014
Transcript
  • 1. Cytori Corporate Overview NASDAQ: CYTX 26th Annual Roth Conference March 12, 2014
  • 2. Safe Harbor Statement This presentation contains certain forward-looking statements about Cytori Therapeutics, Inc. All statements, other than statements of historical fact, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. Such statements are based upon certain assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. The forward-looking statements included in this presentation involve known and unknown risks that relate to Cytoris future events or future financial performance and the actual results could differ materially from those discussed in this presentation. Risks and uncertainties that may cause Cytori's actual results to differ materially from those discussed in the presentation can be found in the "Risk Factors" section of Cytoris Form 10-K, Forms 10-Q and other filings with the United States Securities and Exchange Commission. We would advise reading our most recent annual report on Form 10-K and quarterly report on Form 10-Q filed with the United States Securities and Exchange Commission for a more detailed description of these risks. The forward-looking statements contained in this presentation represent Cytoris estimates and assumptions only as of the date of this presentation and Cytori undertakes no duty or obligation to update or revise publicly any forward-looking statements contained in this presentation as a result of new information, future events or changes in Cytoris expectations.
  • 3. Cytori Investment Summary Highlights Phase II U.S. heart failure trial U.S. government contract (BARDA) for thermal burns Pipeline of therapeutic indications from independent studies Adipose-derived cell therapy with device model Cardiovascular disease & soft tissue injury Product & contract revenue partially offsets cash burn Thousands of patients treated worldwide
  • 4. Cytori Cell Therapy Mechanisms Improve blood flow Modulate inflammation Wound healing Autologous Virtually off the shelf Multiple cell types = multiple mechanisms
  • 5. System: Low six figure ASP Next-generation system COGS < $10,000 Per-procedure consumable: $8,000-$12,000 for vascular indications $2,000-$3,000 for soft tissue >80% GM Cell therapies via proprietary device & single-use consumables = Favorable pricing and margin opportunity Cytori Cell Therapy: Commercial Model & Economics
  • 6. Therapeutic Focus CARDIAC SOFT TISSUE COMMERCIAL RESEARCH MARKET U.S. Phase II in CHF Long term data from CHF and AMI trials in EU Burns: U.S. govt contract worth up to $106 MM Hamstring injury: U.S. trial EU/Japan approvals Research sales 50+ studies completed, ongoing or planned
  • 7. Cardiac Cell Therapy Damage to the heart leads to reduced function, heart failure and death Current therapy does not address damage to the heart muscle
  • 8. PRECISE Pilot Showed Proof-of-Concept PRECISE TRIAL: 27 patient double-blind, randomized, placebo controlled European trial Intramyocardial injection using electromechanical mapping in area with inducible ischemia 18 month data presented, publication in process DATA SUMMARY: Feasibility (Exercise Tolerance) VO2Max (maximum oxygen consumption): improvement (p

Recommended